The treatment of severe asthmatics aged 1-3 years with budesonide administered via Nebuhaler and Laerdal facemask was assessed in a six month, double blind, placebo controlled study.
Recurrent respiratory symptoms are common in early childhood. In recent years, it has been recognised that those with frequent and severe symptoms often have asthma persisting into later childhood.' With increased awareness of the importance of inflammation in the pathogenesis of asthma,2 the use of anti-inflammatory treatment early in the course of the disease might be an opportunity to minimise lung damage and attempt to improve the natural history of what can become a debilitating illness.
This study was designed to provide data on the optimal long term use of steroids in young children with significant morbidity from asthma, using currently available knowledge about steroid usage in this age group. Some studies using oral prednisolone to treat acute symptoms have been disappointing in children under 2 years,3 4 but effective in children over 2 years.4 One study has suggested that intramuscular methylprednisolone is also effective. 5 More recently, there have been favourable reports on the use of inhaled steroid prophylaxis using a spacer device and facemask.f8 These fast and simple delivery systems are an attractive alternative to nebulisers and reduce the possibility of side effects that occur with systemic treatment.
It is recognised that different aetiological factors underlie common respiratory symptoms characteristic of asthma in this age group. Factors such as airway size, previous bronchiolitic illness, and the presence of atopy, have different prognostic implications and might account for the conflicting reports on the effects of nebulised steroids in the first year of life, a time when there is the greatest diagnostic uncertainty.9-"1 Coughing is a particularly prominent symptom in children with persistent asthma,12 although its relationship to wheeze is unclear.'3 Objective measurements in school age children suggest that night time cough is less frequent than that suggested by parents,'4 but in younger children it is often reported as the most troublesome symptom and is disruptive to family life; bronchodilators are often ineffective. 15 This study investigates the use ofbudesonide (Pulmicort, Astra), delivered via a large volume spacer (Nebuhaler, Astra) and Laerdal facemask, in children aged 1-3 years with persistent asthma symptoms including chronic cough. Parallel pug/puff) up to a maximum of four puffs in any four hours, was given through the same delivery system, one puff at a time, for symptomatic treatment.
Children entered the study period only if they had either cough, wheeze, sleep disturbance, or limitation of activity, recorded on at least three days/week for both run-in weeks and if their parents were able to give medications through the Nebuhaler and mask. The study was double blind and children were randomised to receive budesonide (200 pug twice a day) or placebo, in parallel groups for up to six months. They were followed up at six week intervals by the same physician (GJC) and their inhaler technique was checked by a paediatric respiratory nurse specialist (EW/CW). The dosage of study medication was adjusted by the physician or parent, on the basis of clinical need, between 200-400 p,g twice a day of budesonide or 1-2 puffs twice a day of placebo. Oral prednisolone (1-2 mg/kg/day) was given for acute exacerbations of asthma and nebulised terbutaline 2-5-5 mg up to every four hours was prescribed if symptom control was poor. A record was made of all medication prescribed for the treatment of asthma symptoms. Children were withdrawn if symptom control was poor, 19) and bronchodilator usage decreased during the first 11 weeks, and remained at low levels until le orplacebo on lifestyle assessments: within treatment study completion at 24 weeks. In the placebo rn-in and E=last week oftreatment; NS=not significant. group, small improvements in these parameters occurred in the initial weeks of the with budesonide through a Nebuhaler and study, but these were not maintained (data not facemask without any further behavioural shown).
changes.
Three hospital admissions for asthma In the budesonide group, three did not exacerbations occurred during budesonide and complete because of poorly controlled asthma eight during placebo treatment. In addition, and four were withdrawn because parents had there were five episodes of 'respiratory tract difficulties following the study protocol. This infection' causing worsening of symptoms left 13 patients in each group completing all six reported in children receiving budesonide and months of the study. Children completing at 10 such episodes occurred in the placebo least five weeks of the study were to be group. The only drug related adverse event was included in the intention to treat analysis. a case of facial skin rash in the budesonide Diary cards were, however, not retrieved group. This resolved after the parents were from three non-compliant families in the reminded to wipe their child's face after budesonide group, and the diary of the child administering the study medication.
withdrawn because of screaming contained Treatment was considered beneficial by the insufficient data. This left 17 children in the doctor (GJC) in nine out of 13 receiving budesonide group and 19 in the placebo group budesonide and four out of 13 Only those causing a marked increase in asthma symptoms and those precipitating the most severe exacerbations of asthma resulting in hospital admission were recorded. As yet, there is no good evidence that regular prophylactic treatment in the preschool age group is useful in preventing asthma attacks, but the decreased number of acute respiratory episodes in the children receiving budesonide suggests that this probably happened in our study.
It is essential when using inhaled steroids, to use the least amount of medication necessary to control symptoms to minimise the possibility of systemic side effects. Dose response studies suggest that clinically important side effects occur when more than 800 [ig/day of inhaled corticosteroids are used.18 The individual sensitivity to steroidal side effects varies between patients and there is some evidence for intrasubject differences in the sensitivity to different steroid compounds.19
Recommended administered doses for school age children are not necessarily applicable to younger children inhaling medication through a spacer adapted by the attachment of a facemask. A recent study attempting to quantify drug delivery through this type of delivery system suggested that 9-3% of a 1 mg dose of sodium cromoglycate was delivered using a tidal volume of 50 ml.20 Increasing the dead space between the chamber valve and 'face' and agitating the chamber caused large decreases in drug delivery. Hence, the amount of drug reaching the lungs is probably much less.21 The administration of inhaled medication in this age group is much more of an art than a science, and it is very likely that delivered doses vary widely between and within children. Our clinical impression is that 200 pLg twice a day is usually the minimal dose necessary to control symptoms in this group of children with severe asthma.
Measurement of adrenal function is advised in children receiving inhaled steroids. 
